hotspot -WSS

hotspot

author：comprehensive 2025-10-02 00:52:09 - browse：11458

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Hospitals, health systems can help patients avoid medical debt

WSS

Will biotech layoffs continue through 2023?

CDC: Cases of alpha

CDC: Cases of alpha

Trump allegedly attempted to have surveillance video deleted: Special Counsel

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Alexander Hamilton and the argument for universal insurance

focus

hotspot

knowledge

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Doctors on social media are being harassed and cyberbullied

Hepatitis C has a cure — but many Americans still lack access to it

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Wikipedia

Report cites 'urgent' need to recruit more diverse clinical trial participants

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Will biotech layoffs continue through 2023?

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Too many hospitalized Covid

STAT Boddities: What happens to the brain when we get scared?

entertainment

leisure time

hotspot

focus